Cindy Eckert

Last updated
Cindy Eckert
Cindy Eckert on Ashley Graham.jpg
Born
New York, U.S.
Other namesCindy Whitehead
Education Marymount University (BBA)
Parent

Cindy Eckert is an American entrepreneur known for founding Sprout Pharmaceuticals. She subsequently founded The Pink Ceiling which invests in companies founded by, or delivering products for, women. [1] In November 2017, Eckert re-acquired Sprout Pharmaceuticals as part of a lawsuit settlement, and the rights to its drug Addyi, from Valeant after Valeant's stock collapsed due to insider trading and price jacking allegations. [2] [3] [4] [5] [6] [ excessive citations ]

Contents

Early life and education

Cindy Eckert was born in Western New York. According to a New York Times profile piece, she attended a different school each year from the fourth grade through the twelfth. During those years she lived overseas where her father, Fred J. Eckert, served as a U.S. Ambassador to Fiji. [7] She earned a Bachelor of Business Administration from Marymount University. [8] [9]

Career

Eckert began her career with Merck, before moving on to work with smaller, specialty pharmaceutical companies Dura and Elan. [8] After a stint with QVC, Eckert found Slate Pharmaceuticals and Sprout Pharmaceuticals. [1]

She sold Sprout to Valeant in 2015 after the company won FDA approval for the drug Addyi, the first drug designed to enhance female libido. [10] Prior to founding Sprout, Eckert co-founded Slate Pharmaceuticals in 2007. Slate was focused on men's sexual health with an FDA approved long acting testosterone product, Testopel. Slate sold in 2011 to Actient Pharmaceuticals. [11]

Eckert established an investment firm called The Pink Ceiling in 2016 after the most recent exit, when she sold Sprout Pharmaceuticals to Valeant Pharmaceuticals for $1 billion. [12] In November 2017, Eckert re-acquired Sprout Pharmaceuticals from Valeant for "almost nothing" as part of a settlement of a lawsuit, according to Bloomberg News. [2] Valeant's stock had collapsed nearly 80% from the acquisition price due to a large financial engineering and price jacking scandal. [6]

In 2018, Eckert formally changed her name from Cindy Whitehead. [13]

The Pink Ceiling

Eckert launched the Pink Ceiling in order to improve access to capital for female-led start-ups. [1] “The injustice I’m fighting with the Pink Ceiling is not only women’s limited access to capital, but also their limited access to mentors,” she told Entrepreneur Magazine. [1] Eckert works with a team of women to determine which female-led companies will be the recipients of venture capital funding. [14] [15]

To date, The Pink Ceiling has invested in eleven start-ups, with public announcements on their involvement with Undercover Colors (a company that is developing wearable nail tech to detect the presence of a date rape drug in drinks), [12] Lia Diagnostics (which produces a flushable pregnancy test), [16] Intuitap (which has a medical device aimed to streamline the spinal tap procedure), [1] and Pursuit (which is developing a patented technology to improve four different aspects of sleep) [17]

The Pink Ceiling's affiliated incubator, called the “Pinkubator” because of its female focus, is located in Raleigh, North Carolina. The “Pinkubator” was established to provide female-focused entrepreneurs with direct access to mentors, investment opportunities, and business development guidance. [8]

Controversy

Eckert's drug Addyi has faced rampant criticism from scientists and physicians due to lack of efficacy and a PR campaign waged by her company Sprout Pharmaceuticals against the FDA. [18] [19] [20] [21] Critics have said that it shows the FDA caving to social pressure over the actual benefits of the drug. [22] [23] As of 2018 only about 600 prescriptions are filled every month according to Bloomberg. [24] In 2020 the FDA sent Sprout a warning letter regarding their marketing of the drug demanding the Sprout create "comprehensive plan for truthful, non-misleading, and complete corrective messages". [25] [26]

Related Research Articles

<span class="mw-page-title-main">Sildenafil</span> Drug for erectile dysfunction and hypertension

Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in females. It can be taken orally, intravenously, or through the sublingual route. Onset when taken orally is typically within twenty minutes and lasts for about two hours.

<span class="mw-page-title-main">Bausch & Lomb</span> American-Canadian eye health company

Bausch + Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

Biovail Corporation was a Canadian pharmaceutical company, operating internationally in all aspects of pharmaceutical products. Its major production facility was located in Steinbach, Manitoba. It merged with Valeant Pharmaceuticals International in 2010.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Barr Pharmaceuticals</span> Former multinational specialty and generic drug manufacturer

Barr Pharmaceuticals was a global specialty and generic drug manufacturer with operations in 30 countries.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Flibanserin</span> Medication

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth.

<span class="mw-page-title-main">J. Michael Pearson</span>

J. Michael Pearson is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Philidor Rx Services is a Pennsylvania-licensed specialty online pharmacy, which mainly sold Valeant Pharmaceuticals International Inc drugs directly to patients and handled insurance claims on the customers' behalf.

BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment. Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

Drugs and sexual desire is about sexual desire being manipulated through drugs from various approaches. Sexual desire is generated under the effects from sex hormones and microcircuits from brain regions. Neurotransmitters play essential roles in stimulating and inhibiting the processes that lead to libido production in both men and women. For instance, a positive stimulation is modulated by dopamine from the medial preoptic area in the hypothalamus and norepinephrine. At the same time, inhibition occurs when prolactin and serotonin are released for action.

References

  1. 1 2 3 4 5 "This Entrepreneur Who Sold Her Company for $1 Billion Wants You to Throw Out the Unwritten Rules That Hold You Back". Entrepreneur.com. 14 July 2017. Retrieved 2017-08-05.
  2. 1 2 "Valeant Gives $1 Billion Female Libido Pill Back to Old Owners". Bloomberg. 6 November 2017. Retrieved 2018-01-23.
  3. ↑ "Arrogance and Greed: Ackman, Valeant Pay $290M to End Allergan Insider Trading Lawsuit". BioSpace. Retrieved 2021-06-03.
  4. ↑ "Ackman's Pershing Square, Valeant to appear in court to discuss an insider trading lawsuit settlement". CNBC. 2018-01-03. Retrieved 2021-06-03.
  5. ↑ "Anger Behind the Scenes When Valeant Jacked Up Price by 2,700% for Lead Poisoning Drug". BioSpace. Retrieved 2021-06-03.
  6. 1 2 Morgenson, Gretchen (2016-07-29). "How Valeant Cashed In Twice on Higher Drug Prices". The New York Times. ISSN   0362-4331 . Retrieved 2021-06-03.
  7. ↑ Bryant, Adam (30 September 2016). "Cindy Whitehead: No Nickname? Just Leave That to Me". The New York Times. Retrieved 2017-08-05.
  8. 1 2 3 "Woman behind female libido drug launches 'Pinkubator' for women-focused businesses". NewsObserver.com. Retrieved 2017-08-05.
  9. ↑ "How Did Cindy Eckert And Her Empire Win Prejudice And Skeptical Investors?". 13 October 2020. Retrieved 2021-04-11.
  10. ↑ "CEO of company behind Addyi says female sexuality is about biology, not just psychology". The New York Times . Retrieved 2017-08-05.
  11. ↑ "Company Overview of Slate Pharmaceuticals, Inc". Bloomberg.com. Retrieved 2017-08-05.
  12. 1 2 "The woman behind 'female Viagra' sold her company for $1 billion — that's when everything fell apart". BusinessInsider.com. Retrieved 2017-08-05.
  13. ↑ "'Female Viagra' Founder Is Back as CEO After Valeant Gave the Billion-Dollar Drug Back for Free". Fortune.com. Retrieved 2018-06-13.
  14. ↑ "How I Get It Done: Cindy Whitehead, the Creator of 'Female Viagra'". NYMag.com. 10 October 2016. Retrieved 2017-08-11.
  15. ↑ "Exclusive: The Woman Behind the 'Female Viagra' Has a New Venture". Fortune.com. Retrieved 2017-08-11.
  16. ↑ "Philly startup creates new pregnancy test". Philly.com. 16 June 2015. Retrieved 2017-08-11.
  17. ↑ "Unapologetically Pink". FacesOfFounders.com. Retrieved 2017-08-11.
  18. ↑ Baid, Rashmi; Agarwal, Rakesh (2018). "Flibanserin: A controversial drug for female hypoactive sexual desire disorder". Industrial Psychiatry Journal. 27 (1): 154–157. doi: 10.4103/ipj.ipj_20_16 . ISSN   0972-6748. PMC   6198608 . PMID   30416308.
  19. ↑ says, Mark Thorson (2019-04-11). "FDA chastises Addyi maker over trying to remove alcohol safety warning". STAT. Retrieved 2021-06-03.
  20. ↑ Schulte, Brigid; Dennis, Brady (2015-08-18). "FDA approves controversial drug for women with low sex drives". Washington Post. ISSN   0190-8286 . Retrieved 2021-06-03.
  21. ↑ Woloshin, Steven; Schwartz, Lisa M. (2016-04-01). "US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up". JAMA Internal Medicine. 176 (4): 439–442. doi:10.1001/jamainternmed.2016.0073. ISSN   2168-6106. PMID   26926770.
  22. ↑ Nagoski, Emily (2015-02-27). "Opinion | Nothing Is Wrong With Your Sex Drive". The New York Times. ISSN   0362-4331 . Retrieved 2021-06-03.
  23. ↑ "Debate Over Addyi Flares Anew". www.medpagetoday.com. 2016-03-01. Retrieved 2021-06-03.
  24. ↑ Koons, Cynthia (June 13, 2018). "The Women's Libido Pill Is Back, and So Is the Controversy". Bloomberg News .
  25. ↑ "FDA warns Sprout for misleading Addyi come-on". www.raps.org. Retrieved 2021-06-03.
  26. ↑ Commissioner, Office of the (2020-03-24). "FDA orders important safety labeling changes for Addyi". FDA. Retrieved 2021-06-03.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.